Ehrlichia
From IDWiki
Ehrlichia
Background
- Causes human monocytotropic ehrlichiosis, aka. "Rocky Mountain spotless fever"
Microbiology
- Small, obligately intracellular Gram-negative bacteria
- Related to Anaplasma and Rickettsia genera
- Includes the following species:
- E. chaffeensis is the most common cause of human infection
- Other species that can cause disease in humans includes E. ewingii, E. muris, E. muris-like agent, E. canis, and E. ruminantium, with slightly different tick vectors and mammalian hosts
- Cells have two ultrastructural forms: larger reticulate cells (RC) and small, dense core cells (DC)
- Intracellularly, they form aggregates called morulae (mulberries)
Epidemiology
- E. chaffeensis is primarily found in south-central and eastern North America
- Rejected by NML for patients from Ontario without travel
- Vectors are a variety of ticks:
- E. chaffeensis is transmitted by Amblyomma americanum ticks (the Lone Star tick)
- E. ewingiiis transmitted by Amblyomma americanum and Dermacentor variabilis
- E. muris is transmitted by Ixodes persulcatus and Haemaphysalis flava
- E. muris-like agent is transmitted by Ixodes scapularis
- Of note, it is not transmitted transovarially in the ticks
- Reservoirs
- The main reservoir is Odocoileus virginianus (white-tailed deer)
- For E. chaffeensis, others include humans, dogs, coyotes, and marsh deer
- For E. ewingii, dogs, humans, and deer
- Rick factors
- Incidence peaks in May to August
- Exposure is rural or suburban, and usually involves recreational, peridomestic, occupational, and military activities
- Therefore, 60% male
Pathophysiology
- After inoculation, spreads lymphangitically and hematogenously to reach and invade macrophages and granulocytes
- Intracellular morulae also found in blood, bone marrow, liver, lymph nodes, spleen, and CSF macrophages
- Affects almost any organ except for endothelium
- Surface porin proteins are responsible for antigenic variation and host cell adhesion
- The dense core cells also secrete TRP120, which is involved adhesion but also has effects on host cell DNA and DNA transcription
- DC cells predominate soon after infection, then give way to RC cells
- Most of the pathology is caused by host responses, including toxic shock
- Increased TNF-alpha, IL 1-alpha and 1-beta, IL-6, IL-10, and defective Th1 cytokines (IFN-gamma and IL-2)
Clinical Manifestations
E. chaffeensis (human monocytotropic ehrlichiosis)
- Usually causes a mild-to-severe multisystem illness in immunocompetent
- Can cause overwhelming infection in immunosuppressed, especially HIV/AIDS
- Incubation period of 7 days
- Fever, headache, myalgias, and malaise are most common
- Nausea and vomiting in a half, and weight loss
- Can also have diarrhea, rash, cough, altered mental status
- Rash is maculopapular or petechial, and more frequent in children
- Often accompanied by leukopenia, thrombocytopenia, and anemia
- Likely from peripheral consumption rather than bone marrow suppression
- Causes neutropenia and lymphopenia
- Thrombocytopenia usually not severe
- Bone marrow may show a compensatory hypercellularity
- Elevated liver enzymes is almost universal, and AKI in a third of patients
- Severe complications include ARDS, DIC, and death
- Also, hemophagocytic lymphohistiocytosis with E. chaffeensis
- 50% of cases require hospitalization, and 10% have severe complications, and 2-3% die
- The illness usually lasts about 3 weeks (1 week in hospital), followed by prolonged convalescence
E. ewingii and E. muris
- Mostly affects immunocompromised patients
- Presents similarly to HME, but less severe
Differential Diagnosis
Diagnosis
- Should be treated empirically without waiting for diagnosis
- Major method of diagnosis is IFA serology, looking for a fourfold rise in titres over the course of disease, with a minimum peak of 1:64
- Usually peaks at 6 weeks
- Diagnosis can be suggested by morulae on blood film (in monocytes), but insensitive unless overwhelming infection
- Culture not used outside of research
- PCR is possible
Management
- Doxycycline 100 mg po bid
- Can use rifampin as second-line, for pregnant women and children